Cumulative experience in the detection of antiplatelet antibody in 234 patients with idiopathic thrombocytopenic purpura, systemic lupus erythematosus and other clinical disorders

Karpatkin, Simon; Strick, N.; Karpatkin, Margaret B.; Siskind, Gregory W.

doi:10.1016/0002-9343(72)90084-8

Cited by 163 publications

(86 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Increased PF3 activity, indicated by a shortening of the Russell's viper venom (Stypven) time, was considered positive [54]. This assay was refined with a neutralization [55] or IgG isolation step [56].…”

Section: Patch Testmentioning

confidence: 99%

Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia

Arnold

Nazi

Warkentin

et al. 2013

Transfusion Medicine Reviews

153

144

View full text Add to dashboard Cite

Drug-induced immune thrombocytopenia (DITP) is a challenging clinical problem that is underrecognized, difficult to diagnose and associated with severe bleeding complications. DITP may be caused by classic drug-dependent platelet antibodies (eg, quinine); haptens (eg, penicillin); fibandependent antibodies (eg, tirofiban); monoclonal antibodies (eg, abciximab); autoantibody formation (eg, gold); and immune complex formation (eg, heparin). A thorough clinical history is essential in establishing the diagnosis of DITP and should include exposures to prescription medications, herbal preparations and even certain foods and beverages. Clinical and laboratory criteria have been established to determine the likelihood of a drug being the cause of thrombocytopenia, but these criteria can only be applied retrospectively. The most commonly implicated drugs include quinine, quinidine, trimethoprim/sulfamethoxazole and vancomycin. We propose a practical approach to the diagnosis of the patient with suspected DITP. Key features are: the presence of severe thrombocytopenia (platelet nadir <20 × 10 9 /L); bleeding complications; onset 5 to 10 days after first drug exposure, or within hours of subsequent exposures or after first exposure to fibans or abciximab; and exposure to drugs that have been previously implicated in DITP reactions. Treatment involves stopping the drug(s), administering platelet transfusions or other therapies if bleeding is present and counselling on future drug avoidance. The diagnosis can be confirmed by a positive drug re-challenge, which is often impractical, or by demonstrating drug-dependent platelet reactive antibodies in vitro. Current test methods, which are mostly flow cytometry-based, must show drug-dependence, immunoglobulin binding, platelet specificity and *

show abstract

Section: Patch Testmentioning

confidence: 99%

Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia

Arnold

Nazi

Warkentin

et al. 2013

Transfusion Medicine Reviews

153

144

View full text Add to dashboard Cite

show abstract

“…PLT ab are found positive in 65% of ITP patients [29], similar to ITP-like ones (75%). Response to Cs was observed in 7 of 8 (87%) PLT ab-positive and in 2 of 5 (40%) PLT ab-negative cancer patients.…”

Section: Discussionmentioning

confidence: 59%

Successful treatment of idiopathic thrombocytopenic purpura‐like syndrome in a cancer patient with low‐dose interferon: Case report and review of the literature

et al. 2004

View full text Add to dashboard Cite

Idiopathic thrombocytopenic purpura (ITP)-like syndrome is a rare complication of carcinomas, and its treatment usually precedes cancer therapy in order to make further procedures safe. We describe the case of a 78-year-old man with a small-cell lung cancer of extended stage, associated with ITP-like syndrome, which proved resistant to treatment with corticosteroids and vincristine, short-responsive to IV immunoglobulin, but quickly and steadily responsive to low-dose interferon (ld IFN, 3 million IU, sc, twice weekly, for 8 weeks), until the patient's death, due to his primarily chemoresistant cancer. This case is, to our knowledge, the second reported ITP-like syndrome in a cancer patient who had been successfully treated with ld IFN. The excellent and cost-effective therapeutic index of ld IFN makes it an attractive alternative treatment in patients with this specific complication and calls for further investigation regarding its potential use as a first-line treatment. Am.

show abstract

“…In published studies, the presence of neutrophil-associated Ig was not necessarily associated with decreased neutrophil counts, for only 6 of 29 infants born to mothers alloimmunized to granulocytespecific antigens demonstrated abnormal absolute neutrophil counts (6). Autoimmune neonatal thrombocytopenia may be associated with maternal autoimmune disorders including systemic lupus erythematosus, immune thrombocytopenic purpura, hypothyroidism, lymphoproliferative disorders, or other autoimmune diseases in which IgG class autoantibodies cross the placenta and cause destruction of the infant's platelets (21)(22)(23)(24). Neonatal neutropenia may also be associated with the passage of maternal autoantibodies across the placenta (4,25).…”

Section: Discussionmentioning

confidence: 98%

“…Neonatal neutropenia may also be associated with the passage of maternal autoantibodies across the placenta (4,25). The diagnosis of autoimmune neutropenia, also known as transitory neonatal neutropenia, is dependent upon the demonstration of maternal autoantibodies directed against antigens common to both mother and fetus resulting in destruction of neutrophils (21)(22)(23)(24)(25)(26).…”

Section: Discussionmentioning

confidence: 99%

Platelets and Neutrophils from Healthy Term Neonates Exhibit Increased Levels of Immunoglobulins

et al. 1995

View full text Add to dashboard Cite

Cumulative experience in the detection of antiplatelet antibody in 234 patients with idiopathic thrombocytopenic purpura, systemic lupus erythematosus and other clinical disorders

Cited by 163 publications

References 29 publications

Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia

Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia

Successful treatment of idiopathic thrombocytopenic purpura‐like syndrome in a cancer patient with low‐dose interferon: Case report and review of the literature

Platelets and Neutrophils from Healthy Term Neonates Exhibit Increased Levels of Immunoglobulins

Contact Info

Product

Resources

About